January 2019 in “Nihon Yakuri Gakkai nenkai yoshishu” Current treatments for lower urinary tract symptoms include α1-blockers, 5ARIs, PDE5 inhibitors, anticholinergic agents, and β3-adrenergic receptor agonists.
March 2025 in “Scientific Reports” Menthol-based microemulsions improve skin delivery of finasteride and silodosin.
15 citations
,
November 2015 in “Pharmacopsychiatry” α-Blockers and 5-ARIs for BPH can cause sexual dysfunction, including erectile and ejaculatory issues.
March 2015 in “The Journal of Urology” Finasteride reduces PSA levels by around 40-50% in BPH patients.
August 2025 in “The Journal of Sexual Medicine” Finasteride, dutasteride, and silodosin have the highest risk for causing sexual dysfunction.